0001716947 2026-08-05 2026-08-05 true 0001716947 8-K/A 2026-08-05 Ensysce Biosciences, Inc. DE 001-38306 82-2755287 7946 Ivanhoe Avenue Suite 201 La Jolla CA 92037 (858) 263-4196 N/A false false false false Common Stock, par value $0.0001 per share ENSC NASDAQ false On August 6, 2026, Ensysce Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” or the “Company”), filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “Original 8-K”), which reported information under Items 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 7.01 and 9.01 of Form 8-K. This Current Report on Form 8-K/A (i) files Exhibit 3.3, a Certificate of Correction related to Exhibit 3.2 in the Original 8-K, (ii) files a corrected press release as Exhibit 99.1 and (iii) corrects, from $100,000 to $200,000, a fee identified under Item 1.01 paid to Tungsten Partners LLC. This Current Report on Form 8-K/A should be read in conjunction with the Original 8-K. Except as set forth herein, no modifications have been made to information contained in the Original 8-K